209 related articles for article (PubMed ID: 27060927)
21. Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas.
Holzmayer TA; Hilsenbeck S; Von Hoff DD; Roninson IB
J Natl Cancer Inst; 1992 Oct; 84(19):1486-91. PubMed ID: 1359152
[TBL] [Abstract][Full Text] [Related]
22. Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer.
Christie EL; Pattnaik S; Beach J; Copeland A; Rashoo N; Fereday S; Hendley J; Alsop K; Brady SL; Lamb G; Pandey A; deFazio A; Thorne H; Bild A; Bowtell DDL
Nat Commun; 2019 Mar; 10(1):1295. PubMed ID: 30894541
[TBL] [Abstract][Full Text] [Related]
23. Modulation of drug resistance in ovarian cancer cells by inhibition of protein kinase C-alpha (PKC-α) with small interference RNA (siRNA) agents.
Zhao LJ; Xu H; Qu JW; Zhao WZ; Zhao YB; Wang JH
Asian Pac J Cancer Prev; 2012; 13(8):3631-6. PubMed ID: 23098446
[TBL] [Abstract][Full Text] [Related]
24. Prior appendectomy does not protect against subsequent development of malignant or borderline mucinous ovarian neoplasms.
Elias KM; Labidi-Galy SI; Vitonis AF; Hornick JL; Doyle LA; Hirsch MS; Cramer DW; Drapkin R
Gynecol Oncol; 2014 Feb; 132(2):328-33. PubMed ID: 24342438
[TBL] [Abstract][Full Text] [Related]
25. Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer.
Yang X; Iyer AK; Singh A; Milane L; Choy E; Hornicek FJ; Amiji MM; Duan Z
Pharm Res; 2015 Jun; 32(6):2097-109. PubMed ID: 25515492
[TBL] [Abstract][Full Text] [Related]
26. Survivin transcription is associated with P-glycoprotein/MDR1 overexpression in the multidrug resistance of MCF-7 breast cancer cells.
Liu F; Liu S; He S; Xie Z; Zu X; Jiang Y
Oncol Rep; 2010 May; 23(5):1469-75. PubMed ID: 20372866
[TBL] [Abstract][Full Text] [Related]
27. CDX2 immunoreactivity in primary and metastatic ovarian mucinous tumours.
Fraggetta F; Pelosi G; Cafici A; Scollo P; Nuciforo P; Viale G
Virchows Arch; 2003 Dec; 443(6):782-6. PubMed ID: 14576939
[TBL] [Abstract][Full Text] [Related]
28. Hepatocyte growth factor secreted by ovarian cancer cells stimulates peritoneal implantation via the mesothelial-mesenchymal transition of the peritoneum.
Nakamura M; Ono YJ; Kanemura M; Tanaka T; Hayashi M; Terai Y; Ohmichi M
Gynecol Oncol; 2015 Nov; 139(2):345-54. PubMed ID: 26335595
[TBL] [Abstract][Full Text] [Related]
29. MDR1 and multidrug resistance-associated protein (MRP) gene expression in epithelial ovarian tumors.
Kavallaris M; Leary JA; Barrett JA; Friedlander ML
Cancer Lett; 1996 Apr; 102(1-2):7-16. PubMed ID: 8603381
[TBL] [Abstract][Full Text] [Related]
30. Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells.
Bourguignon LY; Peyrollier K; Xia W; Gilad E
J Biol Chem; 2008 Jun; 283(25):17635-51. PubMed ID: 18441325
[TBL] [Abstract][Full Text] [Related]
31. MDR gene expression analysis of six drug-resistant ovarian cancer cell lines.
Januchowski R; Wojtowicz K; Sujka-Kordowska P; Andrzejewska M; Zabel M
Biomed Res Int; 2013; 2013():241763. PubMed ID: 23484165
[TBL] [Abstract][Full Text] [Related]
32. Chitosan/pshRNA plasmid nanoparticles targeting MDR1 gene reverse paclitaxel resistance in ovarian cancer cells.
Yang Y; Wang Z; Li M; Lu S
J Huazhong Univ Sci Technolog Med Sci; 2009 Apr; 29(2):239-42. PubMed ID: 19399413
[TBL] [Abstract][Full Text] [Related]
33. Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo.
Shi Z; Liang YJ; Chen ZS; Wang XW; Wang XH; Ding Y; Chen LM; Yang XP; Fu LW
Cancer Biol Ther; 2006 Jan; 5(1):39-47. PubMed ID: 16319528
[TBL] [Abstract][Full Text] [Related]
34. miR-495 sensitizes MDR cancer cells to the combination of doxorubicin and taxol by inhibiting MDR1 expression.
Zou Z; Zou R; Zong D; Shi Y; Chen J; Huang J; Zhu J; Chen L; Bao X; Liu Y; Liu W; Huang W; Hu J; Chen Z; Lao X; Chen C; Huang X; Lu Y; Ni X; Fang D; Wu D; Lu S; Jiang M; Qiu C; Wu Y; Qiu Q; Dong Y; Su Y; Zhao C; Zhong Z; Cai J; Liang Y
J Cell Mol Med; 2017 Sep; 21(9):1929-1943. PubMed ID: 28411377
[TBL] [Abstract][Full Text] [Related]
35. ETV5 transcription factor is overexpressed in ovarian cancer and regulates cell adhesion in ovarian cancer cells.
Llauradó M; Abal M; Castellví J; Cabrera S; Gil-Moreno A; Pérez-Benavente A; Colás E; Doll A; Dolcet X; Matias-Guiu X; Vazquez-Levin M; Reventós J; Ruiz A
Int J Cancer; 2012 Apr; 130(7):1532-43. PubMed ID: 21520040
[TBL] [Abstract][Full Text] [Related]
36. Chemosensitisation of spontaneous multidrug resistance by a 1,4-dihydropyridine analogue and verapamil in human glioma cell lines overexpressing MRP or MDR1.
Abe T; Koike K; Ohga T; Kubo T; Wada M; Kohno K; Mori T; Hidaka K; Kuwano M
Br J Cancer; 1995 Aug; 72(2):418-23. PubMed ID: 7640227
[TBL] [Abstract][Full Text] [Related]
37. NANOG regulates epithelial-mesenchymal transition and chemoresistance in ovarian cancer.
Qin S; Li Y; Cao X; Du J; Huang X
Biosci Rep; 2017 Feb; 37(1):. PubMed ID: 27884977
[TBL] [Abstract][Full Text] [Related]
38. p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents.
Thottassery JV; Zambetti GP; Arimori K; Schuetz EG; Schuetz JD
Proc Natl Acad Sci U S A; 1997 Sep; 94(20):11037-42. PubMed ID: 9380755
[TBL] [Abstract][Full Text] [Related]
39. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
40. Podocalyxin-like protein 1 expression and correlation with clinical characteristics in epithelial serous and mucinous ovarian carcinoma and tumor-like lesions.
Ye F; Hu Y; Zhou C; Hu Y; Chen H
Pathobiology; 2012; 79(6):307-13. PubMed ID: 22688257
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
